ERBB2 and invasive ductal breast carcinoma: Do et al. (115) applied MRM-based HER2 measurement to 210 cases of invasive ductal carcinoma, investigating the capacity of quantitative HER2 results to differentiate the FISH status in HER2-equivocal cases (defined as IHC 2+, normally subject follow-up FISH testing).